ES2572919T3 - Composición farmacéutica líquida - Google Patents

Composición farmacéutica líquida Download PDF

Info

Publication number
ES2572919T3
ES2572919T3 ES14169754.0T ES14169754T ES2572919T3 ES 2572919 T3 ES2572919 T3 ES 2572919T3 ES 14169754 T ES14169754 T ES 14169754T ES 2572919 T3 ES2572919 T3 ES 2572919T3
Authority
ES
Spain
Prior art keywords
histidine
suitably
formulations
pharmaceutical composition
liquid pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14169754.0T
Other languages
English (en)
Spanish (es)
Inventor
Gianluca Rinaldi
Silvia Fratarcangeli
Alessandra Del Rio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50774705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2572919(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ares Trading SA filed Critical Ares Trading SA
Application granted granted Critical
Publication of ES2572919T3 publication Critical patent/ES2572919T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES14169754.0T 2014-05-23 2014-05-23 Composición farmacéutica líquida Active ES2572919T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14169754.0A EP2946766B1 (en) 2014-05-23 2014-05-23 Liquid pharmaceutical composition

Publications (1)

Publication Number Publication Date
ES2572919T3 true ES2572919T3 (es) 2016-06-03

Family

ID=50774705

Family Applications (5)

Application Number Title Priority Date Filing Date
ES14169754.0T Active ES2572919T3 (es) 2014-05-23 2014-05-23 Composición farmacéutica líquida
ES19215036T Active ES2955316T3 (es) 2014-05-23 2015-05-15 Composición farmacéutica líquida de adalimumab
ES18169979T Active ES2928738T3 (es) 2014-05-23 2015-05-15 Composición farmacéutica líquida
ES25179059T Pending ES3053508T2 (en) 2014-05-23 2015-05-15 Liquid pharmaceutical composition of adalimumab
ES15724974.9T Active ES2683194T3 (es) 2014-05-23 2015-05-15 Composición farmacéutica líquida

Family Applications After (4)

Application Number Title Priority Date Filing Date
ES19215036T Active ES2955316T3 (es) 2014-05-23 2015-05-15 Composición farmacéutica líquida de adalimumab
ES18169979T Active ES2928738T3 (es) 2014-05-23 2015-05-15 Composición farmacéutica líquida
ES25179059T Pending ES3053508T2 (en) 2014-05-23 2015-05-15 Liquid pharmaceutical composition of adalimumab
ES15724974.9T Active ES2683194T3 (es) 2014-05-23 2015-05-15 Composición farmacéutica líquida

Country Status (21)

Country Link
US (5) US10493152B2 (enExample)
EP (6) EP2946766B1 (enExample)
JP (3) JP2017516847A (enExample)
CN (2) CN106659781A (enExample)
AU (4) AU2015263246B2 (enExample)
CA (2) CA3050875A1 (enExample)
CY (1) CY1120488T1 (enExample)
DE (2) DE23189888T1 (enExample)
DK (3) DK3148510T3 (enExample)
ES (5) ES2572919T3 (enExample)
HK (1) HK1257026A1 (enExample)
HR (1) HRP20181226T1 (enExample)
HU (1) HUE040097T2 (enExample)
IL (1) IL249117B2 (enExample)
LT (1) LT3148510T (enExample)
PL (1) PL3148510T3 (enExample)
PT (1) PT3148510T (enExample)
RS (1) RS57772B1 (enExample)
SI (1) SI3148510T1 (enExample)
SM (1) SMT201800413T1 (enExample)
WO (1) WO2015177058A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
PL2946765T3 (pl) * 2014-05-23 2017-08-31 Ares Trading S.A. Ciekła kompozycja farmaceutyczna
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
ES2938608T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
EP3773675B1 (en) 2018-03-29 2024-12-04 Airway Therapeutics, Inc. Systems and methods for characterizing surfactant protein d (sp-d) oligomers
IL277468B2 (en) * 2018-03-29 2024-09-01 Airway Therapeutics Inc Methods and compositions comprising surfactant protein d (sp-d)
WO2020138517A1 (ko) * 2018-12-24 2020-07-02 삼성바이오에피스 주식회사 항-TNFα 항체를 포함하는 약제학적 조성물
CA3125927A1 (en) * 2019-01-11 2020-07-16 Samsung Bioepis Co., Ltd. Pharmaceutical composition comprising antibody, device comprising same, and use thereof
CN113727730A (zh) * 2019-03-18 2021-11-30 阿尔沃科技Hf公司 高浓度TNFα抗体的含水制剂
CN115429751B (zh) * 2022-09-21 2023-11-17 景泽生物医药(合肥)股份有限公司 一种人重组卵泡刺激素注射剂及其制备方法
WO2025038671A2 (en) * 2023-08-15 2025-02-20 Amgen Inc. Acidic buffered intravenous solution stabilizers for use in methods of treatment

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU230048B1 (hu) 1996-02-09 2015-06-29 Abbvie Biotechnology Ltd Humán TNFalfa-kötő antitestek alkalmazása
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5900404A (en) 1997-08-15 1999-05-04 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2004229335C1 (en) * 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
MX2007000891A (es) * 2004-07-23 2007-04-18 Genentech Inc Cristalizacion de anticuerpos o fragmentos de ellos.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
LT2620450T (lt) 2005-03-08 2019-02-11 Pfizer Products Inc. Anti-ctla-4 antikūnų kompozicijos
DK2390267T3 (da) 2005-06-07 2013-08-26 Esbatech A Novartis Co Llc Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
RU2011124527A (ru) 2008-11-17 2012-12-27 Дженентек, Инк. Способ и композиция для уменьшения агрегации макромолекулы в физиологических условиях
NZ595694A (en) 2009-05-04 2013-09-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
EP3409289B1 (en) * 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
BR112012022223B1 (pt) 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
CA2792125C (en) 2010-03-22 2019-02-12 Genentech, Inc. Compositions and methods useful for stabilizing protein-containing formulations
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
CN103458926B (zh) 2010-11-11 2016-10-26 艾伯维生物技术有限公司 改进的高浓度抗TNF α 抗体液体制剂
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
MX421100B (es) 2011-07-01 2025-02-10 Biogen Ma Inc Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
US10093728B2 (en) * 2012-03-07 2018-10-09 Cadila Healthcare Limited Pharmaceutical formulations of TNF-alpha antibodies
US20150150982A1 (en) * 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
MX2015003007A (es) 2012-09-07 2015-06-05 Coherus Biosciences Inc Formulaciones acuosas estables de adalimumab.
CN104768578A (zh) 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
AU2013337644A1 (en) 2012-11-01 2015-05-07 Abbvie Inc. Stable Dual Variable Domain Immunoglobulin protein formulations
CN104707146B (zh) 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
IN2014MU00610A (enExample) 2014-02-21 2015-09-25 Tata Motors Ltd
EP3125928A4 (en) 2014-04-02 2017-11-29 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
PL2946765T3 (pl) 2014-05-23 2017-08-31 Ares Trading S.A. Ciekła kompozycja farmaceutyczna
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
CN110167531B (zh) 2017-01-11 2025-06-03 赛特瑞恩股份有限公司 稳定的液体调配物
WO2021182874A1 (ko) 2020-03-13 2021-09-16 삼성바이오에피스 주식회사 안정성이 증진된 액상 약제학적 조성물

Also Published As

Publication number Publication date
US20230061801A1 (en) 2023-03-02
CA3050875A1 (en) 2015-11-26
EP2946766A1 (en) 2015-11-25
EP2946766B1 (en) 2016-03-02
ES2928738T3 (es) 2022-11-22
RS57772B1 (sr) 2018-12-31
US20230338527A1 (en) 2023-10-26
HUE040097T2 (hu) 2019-02-28
EP4249060A3 (en) 2024-01-03
EP4585614A3 (en) 2025-10-29
US20170189527A1 (en) 2017-07-06
DE25179059T1 (de) 2025-08-28
HRP20181226T1 (hr) 2018-10-19
US11752209B2 (en) 2023-09-12
CY1120488T1 (el) 2019-07-10
EP3659582A1 (en) 2020-06-03
AU2020201090A1 (en) 2020-03-05
JP6962984B2 (ja) 2021-11-05
DK3148510T3 (en) 2018-07-16
HK1257026A1 (zh) 2019-10-11
DK201800070U1 (da) 2018-09-18
PT3148510T (pt) 2018-09-28
US11752208B2 (en) 2023-09-12
IL249117A0 (en) 2017-01-31
DK201800070Y8 (da) 2019-07-09
EP3403646B1 (en) 2022-09-28
EP4585614A2 (en) 2025-07-16
CA2947487A1 (en) 2015-11-26
ES2955316T3 (es) 2023-11-30
JP2017516847A (ja) 2017-06-22
SMT201800413T1 (it) 2018-11-09
CA2947487C (en) 2019-09-24
AU2018222887B2 (en) 2020-02-27
EP3659582B1 (en) 2023-08-16
EP4249060A2 (en) 2023-09-27
DK201800071U1 (da) 2018-12-05
AU2015263246B2 (en) 2018-06-21
US10772961B2 (en) 2020-09-15
US12109267B2 (en) 2024-10-08
ES2683194T3 (es) 2018-09-25
EP3148510B1 (en) 2018-06-27
AU2015263246A1 (en) 2016-11-17
JP2020033361A (ja) 2020-03-05
AU2022203863A1 (en) 2022-06-23
CN108785670A (zh) 2018-11-13
US10493152B2 (en) 2019-12-03
DK201800070Y4 (da) 2018-12-13
DK201800071Y4 (da) 2018-12-13
WO2015177058A1 (en) 2015-11-26
IL249117B2 (en) 2024-11-01
US20210023215A1 (en) 2021-01-28
CN106659781A (zh) 2017-05-10
JP2022003091A (ja) 2022-01-11
LT3148510T (lt) 2018-10-10
ES3053508T2 (en) 2026-01-22
PL3148510T3 (pl) 2018-11-30
EP3403646A1 (en) 2018-11-21
SI3148510T1 (sl) 2018-10-30
AU2018222887A1 (en) 2018-09-13
US20200085948A1 (en) 2020-03-19
DE23189888T1 (de) 2024-03-21
IL249117B1 (en) 2024-07-01
EP3148510A1 (en) 2017-04-05
AU2020201090B2 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
ES2600488T3 (es) Composición farmacéutica líquida
US11752209B2 (en) Liquid pharmaceutical composition
ES2607489T3 (es) Composición farmacéutica líquida
HK40030135A (en) Liquid pharmaceutical composition